We are conducting a phase III randomised trial to determine whether anti-PD-1 inhibitor Sintilimab monotherapy can improve disease free survival (DFS) compared with standard adjuvant chemotherapy in stage III colon cancer patients with dMMR. Methods: This is an open-label, multicentre, randomised ...
Colon cancer during pregnancy Leucovorin, the reduced form offolic acid, potentiates the activity of 5-FU by further inhibitingDNA synthesis[216]. Leucovorin with 5-FU significantly prolongs survival for Dukes B and C stagecolon canceras compared with controls not receiving adjuvant chemotherapy[245,...
Prediction of overall survival in stage II and III colon cancer through machine learning of rapidly-acquired proteomics Kailun Xu Xiaoyang Yin Yingkuan Shao CorrespondenceOpen Access13 Aug 2024Cell Discovery Volume: 10, P: 85 Western lifestyle, metaflammation and the cell of origin of colon cance...
Surgery is the only curative modality for localized colon cancer (stage I-III). Surgical resection potentially provides the only curative option for patients with limited metastatic disease in liver and/or lung (stage IV disease). Surgical options include the following: Right hemicolectomy: For lesi...
Researchers Take Aim at Early-stage Colon Cancer by Working on New Endoscope Device A new European project aims to develop an innovative endoscope device that can detect and diagnose colorectal cancer in its early stages. Called PICCOLO, the project is funded under the European Union’s Horizon ...
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. PURPOSE: Regular physical activity reduces the risk of developing colon cancer, however, its influence on patients with established disease is unknown. PAT... Meyerhardt...
In CheckMate 142, patients with metastatic MSI-H/dMMR colorectal cancer were treated intravenously with nivolumab (3 mg/kg every 2 weeks) plus low-dose ipilimumab (1 mg/kg every 6 weeks) until disease progression or unacceptable toxicity. In all, 58% of patients responded and 22% had stable...
Panelists discuss how Minimal Residual Disease (MRD) and circulating tumor DNA (ctDNA) testing are revolutionizing colon cancer management through improved risk stratification, treatment selection, and surveillance strategies. This is a modal window. This video is either unavailable or not supported in...
NMPA) has accepted and granted priority review to the new drug application (NDA) for ipilimumab injection (IBI310) in combination with sintilimab (Tyvyt) as neoadjuvant treatment for patients with resectable microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMM...
BMC Cancer (2021) 21:529 https://doi.org/10.1186/s12885-021-08183-y RESEARCH ARTICLE Open Access Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study Jolanta Żok1, Michał Bieńkowski2, ...